NEW YORK, June 27, 2026, 09:04 EDT
- Eli Lilly and Company NYSE:LLY finished Friday at $1,208.12, up 7.13%. That move added about $75.7 billion in market value for the drugmaker.
- Lilly’s one-day market value jump was roughly 459 times Jaypirca’s $165 million in Q1 sales.
- Medicare’s GLP-1 Bridge launches July 1 and U.S. markets are closed July 3 for the holiday.
Eli Lilly and Company NYSE:LLY closed at $1,208.12 on Friday, up $80.43. Markets in U.S. cash equities were closed Saturday, leaving Friday as the last pricing. About 7.73 million shares traded, coming in at roughly 2.5 times the average volume listed on Google Finance.
Lilly’s blood-cancer drug didn’t just get a $76 billion re-rating overnight. What buyers paid for is the bigger Lilly trade—European oncology news, Medicare obesity coverage just ahead, and a health-care move while tech stumbled.
Jaypirca got the headline. Lilly said the European Medicines Agency’s CHMP gave a positive opinion for Jaypirca in adults with chronic lymphocytic leukemia in any line of therapy, no matter if they were treated with a BTK inhibitor before. The European Commission is likely to decide in the next one to two months. Lilly also said the same data is in front of the FDA, which is set to make a U.S. call in the second half of 2026.
Lilly Oncology president Jacob Van Naarden called Jaypirca a “meaningful new option.” Paolo Ghia at Università Vita-Salute San Raffaele said trial data pointed to “clinical value” for patients. Eli Lilly and Company
Jaypirca’s first-quarter sales reached $165 million, up 79% year over year. That’s dwarfed by Mounjaro, which generated $8.66 billion, and Zepbound with $4.16 billion in the same period. Lilly’s diabetes and obesity franchise came in about 78 times bigger than Jaypirca’s sales for the quarter.
Lilly’s stock trades as a GLP-1 platform play with upside, not just on oncology like Jaypirca. That’s why price action is in focus. Jaypirca helps the story outside obesity, but it’s still on the market to deliver real numbers on obesity volume and pricing to back up the trillion-dollar valuation.
The new test begins July 1. CMS said its Medicare GLP-1 Bridge will operate until Dec. 31, 2027, separate from standard Part D, and eligible patients will pay $50 per fill. Lilly said qualifying Part D members can get Foundayo or Zepbound for weight control at $50 a month, pending prior authorization and if they meet CMS criteria.
Lilly USA president Ilya Yuffa said about 20 million Medicare patients might fit the clinical criteria for obesity drugs, adding that for many, treatment may be “within reach.” Rachel Batterham, who heads global cardiometabolic health at Lilly, called obesity a “chronic, complex disease.” Eli Lilly and Company
Health-care stocks caught a bid Friday. The Health Care Select Sector SPDR Fund (NYSEARCA:XLV) climbed 2.7%, according to FactSet data cited by MarketWatch, and looked set for its best session since June 4. Lilly outperformed, rallying 7.13%.
Lilly’s run has narrowed the gap. WSJ data puts the average analyst price target at $1,264.92, and the median at $1,280.50. Shares finished Friday at $1,208.12, so Lilly now trades about 4.5% under the average and 5.7% under the median.
Week ahead, Medicare GLP-1 Bridge uptake after July 1 is the first thing to watch. NYSE markets close Friday, July 3, for Independence Day. Lilly’s earnings call is next set for Aug. 5, 10:00 a.m. EDT.
